文献速递妇科

ROS1可能作为宫颈腺癌的预后生物标志物:一项二代测序探索性分析

ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
PubMed 文献 · Gynecol Oncol · 2023-02-17

研究队列腺癌比例高于TCGA队列(44.9% vs 18.0%,P=0.001),ROS1改变数量最多(中位数7.00±2.63)。ROS1改变多的患者复发率更高、总生存更低。

要点

  • 研究队列腺癌比例高于TCGA队列(44.9% vs 18.0%,P=0.001)
  • 研究队列腺癌中ROS1、EGFR、EP300、SHCBP1、ALK和PIK3CA改变多于TCGA队列
  • ROS1改变多的患者5年复发率48.8% vs 14.6%(HR 4.32,95%CI 1.20-15.50,P=0.014),5年生存率70.7% vs 93.1%(HR 7.15,95%CI 1.08-58.22,P=0.032)

核心结论

  • 本探索性分析提示ROS1基因改变可能是日本患者宫颈腺癌的预后生物标志物。

研究设计与样本

  • 本研究为探索性分析,采用二代测序同时检测宫颈腺癌的多个基因突变。
  • 分析基因包括BCAR4、CD274、PDCD1LG2、KRAS、ARID1A、PTEN、ALK、EGFR、ROS1、BRAF、PIK3CA、EP300、EBXW7、SHCBP1、TGFBR2、SMAD4、ERBB2、ERBB3和KLF5。
  • 肿瘤组织和血液样本在初次治疗时获取。
  • 将东海大学49例标本的二代测序分子谱与癌症基因组图谱(TCGA)数据库133例标本的登记数据进行比较。

主要发现

  • 研究队列腺癌比例高于TCGA队列(44.9% vs 18.0%,P=0.001)。
  • 研究队列腺癌中ROS1、EGFR、EP300、SHCBP1、ALK和PIK3CA改变多于TCGA队列。
  • 上述基因中ROS1基因改变数量最多(中位数7.00±2.63)。
  • 研究队列中ROS1改变多的患者复发率显著更高(5年复发率48.8% vs 14.6%;HR 4.32;95%CI 1.20-15.50;P=0.014)。
  • ROS1改变多的患者总生存低于改变少的患者(5年生存率70.7% vs 93.1%;HR 7.15;95%CI 1.08-58.22;P=0.032)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Given the differences in clinical and biological characteristics between cervical adenocarcinoma and squamous cell carcinoma, this study aimed to conduct an exploratory analysis to examine the molecular characteristics of cervical adenocarcinoma in a Japanese population. METHODS: This study explored the simultaneous testing of multiple mutations targeting cervical adenocarcinoma using next-generation sequencing (NGS). The following genes were analyzed: BCAR4, CD274, PDCD1LG2, KRAS, ARID1A, PTEN, ALK, EGFR, ROS1, BRAF, PIK3CA, EP300, EBXW7, SHCBP1, TGFBR2, SMAD4, ERBB2, ERBB3, and KLF5. Tumor tissue and blood samples were obtained at the time of primary treatment. The NGS-based molecular profiles obtained from Tokai University (49 specimens) were compared with the registered data in The Cancer Genome Atlas (TCGA) database (133 specimens). RESULTS: The study cohort had higher rates of adenocarcinoma than the TCGA cohort (44.9% vs. 18.0%; P = 0.001). The adenocarcinomas in the study cohort had more alterations in ROS1, EGFR, EP300, SHCBP1, ALK, and PIK3CA than those in the TCGA cohort. Among them, ROS1 had the highest number of gene alterations (median, 7.00 ± 2.63). In the study cohort, patients with a high number of ROS1 alterations had a significantly higher recurrence rate (5-year recurrence rate, 48.8% vs. 14.6%; hazard ratio [HR], 4.32; 95% confidence interval [CI], 1.20-15.50; P = 0.014) and lower overall survival than those with low alterations (5-year survival rate, 70.7% vs. 93.1%; HR, 7.15; 95% CI, 1.08-58.22; P = 0.032). CONCLUSION: The current exploratory analysis suggests that ROS1 gene alteration may be a prognostic biomarker in cervical adenocarcinoma in Japanese patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Machida H, Matsuo K, Tanaka M, et al. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. Gynecol Oncol. 2023. PMID: 36804622. doi:10.1016/j.ygyno.2023.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。